These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 20058255)

  • 1. The role of flexibility in the rational design of modularly assembled ligands targeting the RNAs that cause the myotonic dystrophies.
    Disney MD; Lee MM; Pushechnikov A; Childs-Disney JL
    Chembiochem; 2010 Feb; 11(3):375-82. PubMed ID: 20058255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Controlling the specificity of modularly assembled small molecules for RNA via ligand module spacing: targeting the RNAs that cause myotonic muscular dystrophy.
    Lee MM; Childs-Disney JL; Pushechnikov A; French JM; Sobczak K; Thornton CA; Disney MD
    J Am Chem Soc; 2009 Dec; 131(47):17464-72. PubMed ID: 19904940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rational design of ligands targeting triplet repeating transcripts that cause RNA dominant disease: application to myotonic muscular dystrophy type 1 and spinocerebellar ataxia type 3.
    Pushechnikov A; Lee MM; Childs-Disney JL; Sobczak K; French JM; Thornton CA; Disney MD
    J Am Chem Soc; 2009 Jul; 131(28):9767-79. PubMed ID: 19552411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rational and modular design of potent ligands targeting the RNA that causes myotonic dystrophy 2.
    Lee MM; Pushechnikov A; Disney MD
    ACS Chem Biol; 2009 May; 4(5):345-55. PubMed ID: 19348464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting toxic RNAs that cause myotonic dystrophy type 1 (DM1) with a bisamidinium inhibitor.
    Wong CH; Nguyen L; Peh J; Luu LM; Sanchez JS; Richardson SL; Tuccinardi T; Tsoi H; Chan WY; Chan HY; Baranger AM; Hergenrother PJ; Zimmerman SC
    J Am Chem Soc; 2014 Apr; 136(17):6355-61. PubMed ID: 24702247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rational design of bioactive, modularly assembled aminoglycosides targeting the RNA that causes myotonic dystrophy type 1.
    Childs-Disney JL; Parkesh R; Nakamori M; Thornton CA; Disney MD
    ACS Chem Biol; 2012 Dec; 7(12):1984-93. PubMed ID: 23130637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design of a bioactive small molecule that targets the myotonic dystrophy type 1 RNA via an RNA motif-ligand database and chemical similarity searching.
    Parkesh R; Childs-Disney JL; Nakamori M; Kumar A; Wang E; Wang T; Hoskins J; Tran T; Housman D; Thornton CA; Disney MD
    J Am Chem Soc; 2012 Mar; 134(10):4731-42. PubMed ID: 22300544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. rbFOX1/MBNL1 competition for CCUG RNA repeats binding contributes to myotonic dystrophy type 1/type 2 differences.
    Sellier C; Cerro-Herreros E; Blatter M; Freyermuth F; Gaucherot A; Ruffenach F; Sarkar P; Puymirat J; Udd B; Day JW; Meola G; Bassez G; Fujimura H; Takahashi MP; Schoser B; Furling D; Artero R; Allain FHT; Llamusi B; Charlet-Berguerand N
    Nat Commun; 2018 May; 9(1):2009. PubMed ID: 29789616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rationally designed small molecules targeting the RNA that causes myotonic dystrophy type 1 are potently bioactive.
    Childs-Disney JL; Hoskins J; Rzuczek SG; Thornton CA; Disney MD
    ACS Chem Biol; 2012 May; 7(5):856-62. PubMed ID: 22332923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. (CCUG)
    Yenigun VB; Sirito M; Amcheslavky A; Czernuszewicz T; Colonques-Bellmunt J; García-Alcover I; Wojciechowska M; Bolduc C; Chen Z; López Castel A; Krahe R; Bergmann A
    Dis Model Mech; 2017 Aug; 10(8):993-1003. PubMed ID: 28623239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RNA Foci, CUGBP1, and ZNF9 are the primary targets of the mutant CUG and CCUG repeats expanded in myotonic dystrophies type 1 and type 2.
    Jones K; Jin B; Iakova P; Huichalaf C; Sarkar P; Schneider-Gold C; Schoser B; Meola G; Shyu AB; Timchenko N; Timchenko L
    Am J Pathol; 2011 Nov; 179(5):2475-89. PubMed ID: 21889481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dynamic combinatorial selection of molecules capable of inhibiting the (CUG) repeat RNA-MBNL1 interaction in vitro: discovery of lead compounds targeting myotonic dystrophy (DM1).
    Gareiss PC; Sobczak K; McNaughton BR; Palde PB; Thornton CA; Miller BL
    J Am Chem Soc; 2008 Dec; 130(48):16254-61. PubMed ID: 18998634
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expanded CCUG repeat RNA expression in Drosophila heart and muscle trigger Myotonic Dystrophy type 1-like phenotypes and activate autophagocytosis genes.
    Cerro-Herreros E; Chakraborty M; Pérez-Alonso M; Artero R; Llamusí B
    Sci Rep; 2017 Jun; 7(1):2843. PubMed ID: 28588248
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Muscleblind-like protein 1 nuclear sequestration is a molecular pathology marker of DM1 and DM2.
    Cardani R; Mancinelli E; Rotondo G; Sansone V; Meola G
    Eur J Histochem; 2006; 50(3):177-82. PubMed ID: 16920640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Small molecule kinase inhibitors alleviate different molecular features of myotonic dystrophy type 1.
    Wojciechowska M; Taylor K; Sobczak K; Napierala M; Krzyzosiak WJ
    RNA Biol; 2014; 11(6):742-54. PubMed ID: 24824895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective inhibition of MBNL1-CCUG interaction by small molecules toward potential therapeutic agents for myotonic dystrophy type 2 (DM2).
    Wong CH; Fu Y; Ramisetty SR; Baranger AM; Zimmerman SC
    Nucleic Acids Res; 2011 Nov; 39(20):8881-90. PubMed ID: 21768123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of MTMR1 expression and correlation with muscle pathological features in juvenile/adult onset myotonic dystrophy type 1 (DM1) and in myotonic dystrophy type 2 (DM2).
    Santoro M; Modoni A; Masciullo M; Gidaro T; Broccolini A; Ricci E; Tonali PA; Silvestri G
    Exp Mol Pathol; 2010 Oct; 89(2):158-68. PubMed ID: 20685272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduction of toxic RNAs in myotonic dystrophies type 1 and type 2 by the RNA helicase p68/DDX5.
    Jones K; Wei C; Schoser B; Meola G; Timchenko N; Timchenko L
    Proc Natl Acad Sci U S A; 2015 Jun; 112(26):8041-5. PubMed ID: 26080402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Muscleblind-like 1 interacts with RNA hairpins in splicing target and pathogenic RNAs.
    Yuan Y; Compton SA; Sobczak K; Stenberg MG; Thornton CA; Griffith JD; Swanson MS
    Nucleic Acids Res; 2007; 35(16):5474-86. PubMed ID: 17702765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Misregulated alternative splicing of BIN1 is associated with T tubule alterations and muscle weakness in myotonic dystrophy.
    Fugier C; Klein AF; Hammer C; Vassilopoulos S; Ivarsson Y; Toussaint A; Tosch V; Vignaud A; Ferry A; Messaddeq N; Kokunai Y; Tsuburaya R; de la Grange P; Dembele D; Francois V; Precigout G; Boulade-Ladame C; Hummel MC; Lopez de Munain A; Sergeant N; Laquerrière A; Thibault C; Deryckere F; Auboeuf D; Garcia L; Zimmermann P; Udd B; Schoser B; Takahashi MP; Nishino I; Bassez G; Laporte J; Furling D; Charlet-Berguerand N
    Nat Med; 2011 Jun; 17(6):720-5. PubMed ID: 21623381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.